{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:20:49Z","timestamp":1781796049366,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"DOI":"10.1007\/s11882-026-01263-8","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T08:52:42Z","timestamp":1772873562000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Investigational Approaches in Treatment of Nonadvanced Mastocytosis"],"prefix":"10.1007","volume":"26","author":[{"given":"Thanai","family":"Pongdee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"issue":"1","key":"1263_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-025-00611-8","volume":"11","author":"C Akin","year":"2025","unstructured":"Akin C, Arock M, Carter MC, George TI, Valent P, Mastocytosis. Nat Rev Dis Primers. 2025;11(1):30. https:\/\/doi.org\/10.1038\/s41572-025-00611-8.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"1263_CR2","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1016\/j.jaci.2022.04.020","volume":"149","author":"C Akin","year":"2022","unstructured":"Akin C, Arock M, Valent P. Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: are we there yet? J Allergy Clin Immunol. 2022;149(6):1912\u20138. https:\/\/doi.org\/10.1016\/j.jaci.2022.04.020.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1263_CR3","doi-asserted-by":"publisher","first-page":"EVIDoa2200339","DOI":"10.1056\/EVIDoa2200339","volume":"2","author":"J Gotlib","year":"2023","unstructured":"Gotlib J, Castells M, Elberink HO, Siebenhaar F, Hartmann K, Broesby-Olsen S, et al. Avapritinib versus Placebo in Indolent Systemic Mastocytosis. NEJM Evid. 2023;2(6):EVIDoa2200339. https:\/\/doi.org\/10.1056\/EVIDoa2200339.","journal-title":"NEJM Evid"},{"key":"1263_CR4","unstructured":"Blueprint Medicines. Ayvakit prescribing information. February 2026. Available at: https:\/\/www.blueprintmedicines.com\/wp-content\/uploads\/uspi\/AYVAKIT.pdf"},{"key":"1263_CR5","unstructured":"Cogent Biosciences. SUMMIT, Press, Release, July. 7, 2025. Available at: https:\/\/investors.cogentbio.com\/news-releases\/news-release-details\/cogent-biosciences-announces-positive-top-line-results-achieving"},{"key":"1263_CR6","doi-asserted-by":"publisher","unstructured":"Tashi T, Hermine O, Castells M, Guilarte M, Sabato V, Maurer M, et al. Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial. Blood. 2023;142. https:\/\/doi.org\/10.1182\/blood-2023-188904.","DOI":"10.1182\/blood-2023-188904"},{"issue":"12","key":"1263_CR7","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ajh.21894","volume":"85","author":"C Paul","year":"2010","unstructured":"Paul C, Sans B, Suarez F, Casassus P, Barete S, Lanternier F, et al. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol. 2010;85(12):921\u20135. https:\/\/doi.org\/10.1002\/ajh.21894.","journal-title":"Am J Hematol"},{"issue":"10069","key":"1263_CR8","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S0140-6736(16)31403-9","volume":"389","author":"O Lortholary","year":"2017","unstructured":"Lortholary O, Chandesris MO, Bulai Livideanu C, Paul C, Guillet G, Jassem E, et al. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet. 2017;389(10069):612\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(16)31403-9.","journal-title":"Lancet"},{"issue":"10","key":"1263_CR9","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1093\/annonc\/mdx290","volume":"28","author":"P Valent","year":"2017","unstructured":"Valent P, Akin C, Hartmann K, George TI, Sotlar K, Peter B, et al. Midostaurin: a magic bullet that blocks mast cell expansion and activation. Ann Oncol. 2017;28(10):2367\u201376. https:\/\/doi.org\/10.1093\/annonc\/mdx290.","journal-title":"Ann Oncol"},{"issue":"11","key":"1263_CR10","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1111\/j.1365-2222.2009.03353.x","volume":"39","author":"MT Krauth","year":"2009","unstructured":"Krauth MT, Mirkina I, Herrmann H, Baumgartner C, Kneidinger M, Valent P. Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells. Clin Exp Allergy. 2009;39(11):1711\u201320. https:\/\/doi.org\/10.1111\/j.1365-2222.2009.03353.x.","journal-title":"Clin Exp Allergy"},{"issue":"26","key":"1263_CR11","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","volume":"374","author":"J Gotlib","year":"2016","unstructured":"Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374(26):2530\u201341. https:\/\/doi.org\/10.1056\/NEJMoa1513098.","journal-title":"N Engl J Med"},{"issue":"12","key":"1263_CR12","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1634\/theoncologist.2018-0222","volume":"23","author":"YL Kasamon","year":"2018","unstructured":"Kasamon YL, Ko CW, Subramaniam S, Ma L, Yang Y, Nie L, et al. FDA approval summary: midostaurin for the treatment of advanced systemic mastocytosis. Oncologist. 2018;23(12):1511\u20139. https:\/\/doi.org\/10.1634\/theoncologist.2018-0222.","journal-title":"Oncologist"},{"issue":"3","key":"1263_CR13","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jaci.2018.06.003","volume":"142","author":"B van Anrooij","year":"2018","unstructured":"van Anrooij B, Oude Elberink JNG, Span LFR, de Monchy JGR, Rosati S, Mulder AB, et al. Midostaurin in patients with indolent systemic mastocytosis: An open-label phase 2 trial. J Allergy Clin Immunol. 2018;142(3):1006\u2013e87. https:\/\/doi.org\/10.1016\/j.jaci.2018.06.003.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"1263_CR14","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1111\/all.12920","volume":"71","author":"B van Anrooij","year":"2016","unstructured":"van Anrooij B, Kluin-Nelemans JC, Safy M, de Flokstra- Blok BM, Oude Elberink JN. Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis. Allergy. 2016;71(11):1585\u201393. https:\/\/doi.org\/10.1111\/all.12920.","journal-title":"Allergy"},{"issue":"7","key":"1263_CR15","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1016\/j.jaip.2023.03.015","volume":"11","author":"MC Dispenza","year":"2023","unstructured":"Dispenza MC, Metcalfe DD, Olivera A. Research advances in mast cell biology and their translation into novel therapies for anaphylaxis. J Allergy Clin Immunol Pract. 2023;11(7):2032\u201342. https:\/\/doi.org\/10.1016\/j.jaip.2023.03.015.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"1263_CR16","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1111\/all.15262","volume":"77","author":"D Alvarado","year":"2022","unstructured":"Alvarado D, Maurer M, Gedrich R, Seibel SB, Murphy MB, Crew L, et al. Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study. Allergy. 2022;77(8):2393\u2013403. https:\/\/doi.org\/10.1111\/all.15262.","journal-title":"Allergy"},{"issue":"5","key":"1263_CR17","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/all.15585","volume":"78","author":"D Terhorst-Molawi","year":"2023","unstructured":"Terhorst-Molawi D, Hawro T, Grekowitz E, Kiefer L, Merchant K, Alvarado D, et al. Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria. Allergy. 2023;78(5):1269\u201379. https:\/\/doi.org\/10.1111\/all.15585.","journal-title":"Allergy"},{"issue":"8","key":"1263_CR18","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1111\/all.16598","volume":"80","author":"M Maurer","year":"2025","unstructured":"Maurer M, Metz M, Anderson J, Talreja N, Young D, Crowley E, et al. Anti-KIT barzolvolimab for chronic spontaneous urticaria. Allergy. 2025;80(8):2178\u201386. https:\/\/doi.org\/10.1111\/all.16598.","journal-title":"Allergy"},{"issue":"19","key":"1263_CR19","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1182\/blood-2018-06-853879","volume":"133","author":"HS Kwon","year":"2019","unstructured":"Kwon HS, Logan AC, Chhabra A, Pang WW, Czechowicz A, Tate K, et al. Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice. Blood. 2019;133(19):2104\u20138. https:\/\/doi.org\/10.1182\/blood-2018-06-853879.","journal-title":"Blood"},{"issue":"4","key":"1263_CR20","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s11010-022-04557-3","volume":"478","author":"KH Kim","year":"2023","unstructured":"Kim KH, Kim JO, Park SG. A fully human anti-c-Kit monoclonal antibody 2G4 inhibits proliferation and degranulation of human mast cells. Mol Cell Biochem. 2023;478(4):861\u201373. https:\/\/doi.org\/10.1007\/s11010-022-04557-3.","journal-title":"Mol Cell Biochem"},{"issue":"10","key":"1263_CR21","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1158\/1078-0432.CCR-16-2152","volume":"23","author":"CA London","year":"2017","unstructured":"London CA, Gardner HL, Rippy S, Post G, La Perle K, Crew L, et al. KTN0158, a humanized anti-KIT monoclonal antibody, demonstrates biologic activity against both normal and malignant canine mast cells. Clin Cancer Res. 2017;23(10):2565\u201374. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2152.","journal-title":"Clin Cancer Res"},{"key":"1263_CR22","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev-immunol-102419-035900","volume":"38","author":"S Duan","year":"2020","unstructured":"Duan S, Paulson JC. Siglecs as immune cell checkpoints in disease. Annu Rev Immunol. 2020;38:365\u201395. https:\/\/doi.org\/10.1146\/annurev-immunol-102419-035900.","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"1263_CR23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.pharmthera.2012.06.005","volume":"135","author":"T Kiwamoto","year":"2012","unstructured":"Kiwamoto T, Kawasaki N, Paulson JC, Bochner BS. Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions. Pharmacol Ther. 2012;135(3):327\u201336. https:\/\/doi.org\/10.1016\/j.pharmthera.2012.06.005.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"1263_CR24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jaci.2007.10.004","volume":"121","author":"H Yokoi","year":"2008","unstructured":"Yokoi H, Choi OH, Hubbard W, Lee HS, Canning BJ, Lee HH, et al. Inhibition of FcepsilonRI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement. J Allergy Clin Immunol. 2008;121(2):499\u2013e5051. https:\/\/doi.org\/10.1016\/j.jaci.2007.10.004.","journal-title":"J Allergy Clin Immunol"},{"key":"1263_CR25","doi-asserted-by":"publisher","first-page":"101104","DOI":"10.1016\/j.mam.2022.101104","volume":"90","author":"BS Bochner","year":"2023","unstructured":"Bochner BS, O\u2019Sullivan JA, Chang AT, Youngblood BA. Siglecs in allergy and asthma. Mol Aspects Med. 2023;90:101104. https:\/\/doi.org\/10.1016\/j.mam.2022.101104.","journal-title":"Mol Aspects Med"},{"issue":"2","key":"1263_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000501637","volume":"180","author":"BA Youngblood","year":"2019","unstructured":"Youngblood BA, Brock EC, Leung J, Falahati R, Bryce PJ, Bright J, et al. AK002, a humanized sialic acid-binding immunoglobulin-like lectin-8 antibody that induces antibody-dependent cell-mediated cytotoxicity against human eosinophils and inhibits mast cell-mediated anaphylaxis in mice. Int Arch Allergy Immunol. 2019;180(2):91\u2013102. https:\/\/doi.org\/10.1159\/000501637.","journal-title":"Int Arch Allergy Immunol"},{"issue":"5","key":"1263_CR27","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/bjd\/ljad191","volume":"189","author":"F Siebenhaar","year":"2023","unstructured":"Siebenhaar F, Altrichter S, Bonnekoh H, Hawro T, Hawro M, Michaelis EG, et al. Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial. Br J Dermatol. 2023;189(5):511\u20139. https:\/\/doi.org\/10.1093\/bjd\/ljad191.","journal-title":"Br J Dermatol"},{"key":"1263_CR28","unstructured":"Taylor NP. https:\/\/www.fiercebiotech.com\/biotech\/allakos-drops-lead-asset-after-midphase-flops-join-litany-letdowns-halves-headcount (2024). Accessed 9\/8\/25 2025."},{"issue":"1","key":"1263_CR29","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41392-023-01608-z","volume":"8","author":"V Panwar","year":"2023","unstructured":"Panwar V, Singh A, Bhatt M, Tonk RK, Azizov S, Raza AS, et al. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal Transduct Target Ther. 2023;8(1):375. https:\/\/doi.org\/10.1038\/s41392-023-01608-z.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"1263_CR30","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nri3901","volume":"15","author":"T Weichhart","year":"2015","unstructured":"Weichhart T, Hengstschlager M, Linke M. Regulation of innate immune cell function by mTOR. Nat Rev Immunol. 2015;15(10):599\u2013614. https:\/\/doi.org\/10.1038\/nri3901.","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"1263_CR31","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1182\/blood.v97.11.3559","volume":"97","author":"ZQ Ning","year":"2001","unstructured":"Ning ZQ, Li J, Arceci RJ. Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. Blood. 2001;97(11):3559\u201367. https:\/\/doi.org\/10.1182\/blood.v97.11.3559.","journal-title":"Blood"},{"issue":"3","key":"1263_CR32","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1182\/blood-2005-06-2433","volume":"108","author":"M Gabillot-Carre","year":"2006","unstructured":"Gabillot-Carre M, Lepelletier Y, Humbert M, de Sepuvelda P, Hamouda NB, Zappulla JP, et al. Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells. Blood. 2006;108(3):1065\u201372. https:\/\/doi.org\/10.1182\/blood-2005-06-2433.","journal-title":"Blood"},{"issue":"2","key":"1263_CR33","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3109\/10428190903486220","volume":"51","author":"SA Parikh","year":"2010","unstructured":"Parikh SA, Kantarjian HM, Richie MA, Cortes JE, Verstovsek S. Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis. Leuk Lymphoma. 2010;51(2):269\u201374. https:\/\/doi.org\/10.3109\/10428190903486220.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"1263_CR34","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/ajh.27323","volume":"99","author":"J Moraly","year":"2024","unstructured":"Moraly J, Rossignol J, Rouzaud C, Gabas T, Bouktit H, Lhermitte L, et al. Efficacy and safety of mammalian target of rapamycin inhibitors in systemic mastocytosis: a nationwide French pilot study. Am J Hematol. 2024;99(6):1095\u2013102. https:\/\/doi.org\/10.1002\/ajh.27323.","journal-title":"Am J Hematol"},{"issue":"6","key":"1263_CR35","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","volume":"37","author":"P Valent","year":"2007","unstructured":"Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, Brockow K, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37(6):435\u201353. https:\/\/doi.org\/10.1111\/j.1365-2362.2007.01807.x.","journal-title":"Eur J Clin Invest"},{"issue":"5","key":"1263_CR36","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/ni.3153","volume":"16","author":"CA Hunter","year":"2015","unstructured":"Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16(5):448\u201357. https:\/\/doi.org\/10.1038\/ni.3153.","journal-title":"Nat Immunol"},{"issue":"2","key":"1263_CR37","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.clim.2005.01.011","volume":"115","author":"K Brockow","year":"2005","unstructured":"Brockow K, Akin C, Huber M, Metcalfe DD. IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin Immunol. 2005;115(2):216\u201323. https:\/\/doi.org\/10.1016\/j.clim.2005.01.011.","journal-title":"Clin Immunol"},{"issue":"1","key":"1263_CR38","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/leu.2015.176","volume":"30","author":"A Mayado","year":"2016","unstructured":"Mayado A, Teodosio C, Garcia-Montero AC, Matito A, Rodriguez-Caballero A, Morgado JM, et al. Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression. Leukemia. 2016;30(1):124\u201330. https:\/\/doi.org\/10.1038\/leu.2015.176.","journal-title":"Leukemia"},{"issue":"6","key":"1263_CR39","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1016\/j.jaci.2015.09.059","volume":"137","author":"A Desai","year":"2016","unstructured":"Desai A, Jung MY, Olivera A, Gilfillan AM, Prussin C, Kirshenbaum AS, et al. IL-6 promotes an increase in human mast cell numbers and reactivity through suppression of suppressor of cytokine signaling 3. J Allergy Clin Immunol. 2016;137(6):1863\u2013e716. https:\/\/doi.org\/10.1016\/j.jaci.2015.09.059.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1263_CR40","doi-asserted-by":"publisher","first-page":"100498","DOI":"10.1016\/j.jacig.2025.100498","volume":"4","author":"HD Komarow","year":"2025","unstructured":"Komarow HD, Wang J, Eisch R, Scott L, Brittain EH, Metcalfe DD. Treatment of indolent systemic mastocytosis with sarilumab is not supported in a randomized trial. J Allergy Clin Immunol Glob. 2025;4(3):100498. https:\/\/doi.org\/10.1016\/j.jacig.2025.100498.","journal-title":"J Allergy Clin Immunol Glob"},{"issue":"9","key":"1263_CR41","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s40265-018-0929-z","volume":"78","author":"YN Lamb","year":"2018","unstructured":"Lamb YN, Deeks ED. Sarilumab: a review in moderate to severe rheumatoid arthritis. Drugs. 2018;78(9):929\u201340. https:\/\/doi.org\/10.1007\/s40265-018-0929-z.","journal-title":"Drugs"},{"issue":"6","key":"1263_CR42","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/all.12842","volume":"71","author":"F Siebenhaar","year":"2016","unstructured":"Siebenhaar F, von Tschirnhaus E, Hartmann K, Rabenhorst A, Staubach P, Peveling-Oberhag A, et al. Development and validation of the mastocytosis quality of life questionnaire: MC-QoL. Allergy. 2016;71(6):869\u201377. https:\/\/doi.org\/10.1111\/all.12842.","journal-title":"Allergy"},{"key":"1263_CR43","doi-asserted-by":"publisher","first-page":"668131","DOI":"10.3389\/fcell.2021.668131","volume":"9","author":"SFH Neys","year":"2021","unstructured":"Neys SFH, Hendriks RW, Corneth OBJ. Targeting Bruton\u2019s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies. Front Cell Dev Biol. 2021;9:668131. https:\/\/doi.org\/10.3389\/fcell.2021.668131.","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"1263_CR44","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.jaci.2023.12.008","volume":"153","author":"JA Bernstein","year":"2024","unstructured":"Bernstein JA, Maurer M, Saini SS. BTK signaling-a crucial link in the pathophysiology of chronic spontaneous urticaria. J Allergy Clin Immunol. 2024;153(5):1229\u201340. https:\/\/doi.org\/10.1016\/j.jaci.2023.12.008.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1263_CR45","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.anai.2024.03.002","volume":"133","author":"EV Lin","year":"2024","unstructured":"Lin EV, Suresh RV, Dispenza MC. Bruton\u2019s tyrosine kinase inhibition for the treatment of allergic disorders. Ann Allergy Asthma Immunol. 2024;133(1):33\u201342. https:\/\/doi.org\/10.1016\/j.anai.2024.03.002.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"9","key":"1263_CR46","doi-asserted-by":"publisher","first-page":"4759","DOI":"10.1172\/JCI138448","volume":"130","author":"MC Dispenza","year":"2020","unstructured":"Dispenza MC, Krier-Burris RA, Chhiba KD, Undem BJ, Robida PA, Bochner BS. Bruton\u2019s tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis. J Clin Invest. 2020;130(9):4759\u201370. https:\/\/doi.org\/10.1172\/JCI138448.","journal-title":"J Clin Invest"},{"key":"1263_CR47","doi-asserted-by":"publisher","unstructured":"Suresh RV, Dunnam C, Vaidya D, Wood RA, Bochner BS, MacGlashan DW Jr., et al. A phase II study of Bruton\u2019s tyrosine kinase inhibition for the prevention of anaphylaxis. J Clin Invest. 2023;133(16). https:\/\/doi.org\/10.1172\/JCI172335.","DOI":"10.1172\/JCI172335"},{"issue":"10","key":"1263_CR48","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1056\/NEJMoa2408792","volume":"392","author":"M Metz","year":"2025","unstructured":"Metz M, Gimenez-Arnau A, Hide M, Lebwohl M, Mosnaim G, Saini S, et al. Remibrutinib in chronic spontaneous urticaria. N Engl J Med. 2025;392(10):984\u201394. https:\/\/doi.org\/10.1056\/NEJMoa2408792.","journal-title":"N Engl J Med"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-026-01263-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-026-01263-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-026-01263-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T08:52:43Z","timestamp":1772873563000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-026-01263-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1263"],"URL":"https:\/\/doi.org\/10.1007\/s11882-026-01263-8","relation":{},"ISSN":["1534-6315"],"issn-type":[{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"20 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Dr. Pongdee reports research grants from Blueprint Medicines, Cogent Biosciences, and Telios Pharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"18"}}